Free tool
FAERS Monitor: Atmeksi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219843 or its brand name (Atmeksi, Methocarbamol). Reports on generic versions are filed under their own applications.
Reports
17,199
Serious
10,693
62% of reports
Hospitalization
5,205
Death reported
1,418
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue1,273
- pain1,245
- nausea1,191
- drug ineffective1,140
- headache973
- diarrhoea882
- off label use837
- fall813
- dyspnoea788
- arthralgia766
- dizziness696
- back pain652
- chronic kidney disease648
- anxiety642
- vomiting623
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 108 |
| 2005 | 134 |
| 2006 | 131 |
| 2007 | 84 |
| 2008 | 134 |
| 2009 | 176 |
| 2010 | 199 |
| 2011 | 253 |
| 2012 | 349 |
| 2013 | 346 |
| 2014 | 378 |
| 2015 | 695 |
| 2016 | 972 |
| 2017 | 845 |
| 2018 | 1,084 |
| 2019 | 1,240 |
| 2020 | 1,353 |
| 2021 | 1,120 |
| 2022 | 1,214 |
| 2023 | 1,273 |
| 2024 | 1,485 |
| 2025 | 1,975 |
| 2026 | 1,651 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,960 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 648 | 10.5 | 9.7 | 5,540 |
| back painSignal | 652 | 3.4 | 3.2 | 1,135 |
| fallSignal | 813 | 3.0 | 2.8 | 1,091 |
| anxietySignal | 642 | 2.8 | 2.6 | 729 |
| painSignal | 1,245 | 2.5 | 2.4 | 1,131 |
| arthralgiaSignal | 766 | 2.3 | 2.1 | 544 |
| fatigueSignal | 1,273 | 2.0 | 1.9 | 660 |
| headache | 973 | 1.9 | 1.8 | 425 |
| nausea | 1,191 | 1.8 | 1.7 | 474 |
| dizziness | 696 | 1.7 | 1.6 | 208 |
| dyspnoea | 788 | 1.7 | 1.6 | 234 |
| diarrhoea | 882 | 1.7 | 1.6 | 245 |
| vomiting | 623 | 1.6 | 1.5 | 151 |
| off label use | 837 | 1.2 | 1.1 | 21 |
| drug ineffective | 1,140 | 1.1 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.